PIPAC-OPC2

PIPAC-OPC2 refers to a Phase 2 clinical trial protocol (NCT03280511) led by Michael Bau Mortensen at Odense University Hospital, evaluating the efficacy of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for peritoneal metastases. PIPAC is an innovative drug delivery method that converts liquid chemotherapy into a pressurized aerosol within the peritoneal cavity during laparoscopy, enhancing drug penetration into subperitoneal tissue. The protocol utilizes different chemotherapy agents based on the primary cancer: oxaliplatin for colorectal and appendiceal metastases, and a combination of cisplatin and doxorubicin for other gastrointestinal, ovarian, or primary peritoneal cancers. This approach is primarily investigated for patients with peritoneal carcinomatosis who are not candidates for or have progressed on standard systemic treatments.

Other names

Pressurized IntraPeritoneal Aerosol ChemotherapyPIPAC